scholarly journals In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.

1985 ◽  
Vol 27 (4) ◽  
pp. 565-569 ◽  
Author(s):  
M Toda ◽  
N Arao ◽  
C Nohara ◽  
K Susaki ◽  
A Tachibana
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities ◽  
In Vitro Studies

scholarly journals SCE-963, a New Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities

1978 ◽  
Vol 14 (4) ◽  
pp. 557-568 ◽  
Author(s):  
K. Tsuchiya ◽  
M. Kida ◽  
M. Kondo ◽  
H. Ono ◽  
M. Takeuchi ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities

scholarly journals In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

1985 ◽  
Vol 27 (2) ◽  
pp. 265-269 ◽  
Author(s):  
G P Bodey ◽  
D H Ho ◽  
B LeBlanc
Keyword(s):  
Broad Spectrum ◽  
In Vitro Studies

scholarly journals Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

1981 ◽  
Vol 19 (1) ◽  
pp. 56-65 ◽  
Author(s):  
K Tsuchiya ◽  
M Kondo ◽  
M Kida ◽  
M Nakao ◽  
T Iwahi ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities

In vitro studies of antioxidant, antidiabetic, and antibacterial activities of Theobroma cacao, Anonna muricata and Clitoria ternatea

2021 ◽  
pp. 101995
Author(s):  
Anastasia Wheni Indrianingsih ◽  
Martha Purnami Wulanjati ◽  
Anjar Windarsih ◽  
Debu Kumar Bhattacharjya ◽  
Toshisada Suzuki ◽  
...  
Keyword(s):  
Theobroma Cacao ◽  
Antibacterial Activities ◽  
In Vitro Studies ◽  
Clitoria Ternatea

scholarly journals In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.

1993 ◽  
Vol 37 (2) ◽  
pp. 301-307 ◽  
Author(s):  
K P Fu ◽  
B D Foleno ◽  
S C Lafredo ◽  
J M LoCoco ◽  
D M Isaacson
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities

In Vitro and In Vivo Antibacterial Activities of Broad Spectrum Quinolones against Clinical Bacterial Isolates

Drugs ◽  
1995 ◽  
Vol 49 (Supplement 2) ◽  
pp. 219-221
Author(s):  
T. Matsumoto ◽  
K. Tateda ◽  
Y. Ishii ◽  
A. Ohno ◽  
S. Miyazaki ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities ◽  
Bacterial Isolates

scholarly journals In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.

1997 ◽  
Vol 41 (12) ◽  
pp. 2742-2748 ◽  
Author(s):  
E Di Modugno ◽  
R Broggio ◽  
I Erbetti ◽  
J Lowther
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Broad Spectrum ◽  
Antibacterial Activities ◽  
Beta Lactam ◽  
Beta Lactamases ◽  
Streptococcus Sanguis ◽  
Spectrum Activity ◽  
Providencia Stuartii

GV129606 is a new parenteral trinem antibiotic belonging to the beta-lactam class. It combines broad-spectrum activity (against gram-negative and -positive bacteria, aerobes and anaerobes), with high potency and resistance to beta-lactamases. Comparative in vitro and in vivo antibacterial activities were determined for GV129606 against more than 400 recent clinical isolates (aerobes, including beta-lactamase producers, and anaerobes), using representative antibacterial agents (meropenem, piperacillin, ceftazidime, cefpirome, ciprofloxacin, and gentamicin for aerobes and metronidazole, cefoxitin, piperacillin, and clindamycin for anaerobes). Against methicillin-susceptible staphylococci and streptococci, GV129606 and meropenem were the most active of the drugs tested. GV129606 showed an MIC for 90% of strains tested (MIC90) ranging from < or =0.015 to 0.06 microg/ml against methicillin-susceptible staphylococci and Streptococcus sanguis, Streptococcus pyogenes, and Streptococcus agalactiae. Against penicillin-susceptible and -resistant Streptococcus pneumoniae isolates, GV129606, meropenem, and cefpirome showed MIC90s of < or =0.015 and 1 microg/ml, respectively. Meropenem was the most active compound against members of the family Enterobacteriaceae with MIC90s of < or =0.5 microg/ml. Against these species, GV129606 possessed activity superior to those of piperacillin, ceftazidime, cefpirome, and gentamicin, with MIC90s of < or =8 microg/ml, but its activity was two- to sixfold less than that of ciprofloxacin (with the exception of Proteus rettgeri and Providencia stuartii). Haemophilus spp., Moraxella catarrhalis, Neisseria gonorrhoeae, and Pseudomonas aeruginosa were also included in the spectrum of GV129606. GV129606 showed good antianaerobe activity, similar to metronidazole. It was stable against all clinically relevant beta-lactamases (similar to meropenem). The in vitro activity was confirmed in vivo against septicemia infections induced in mice by selected gram-positive and -negative bacteria with 50% effective doses (ED50s) of < or =0.05 and < or =0.5 mg/kg of body weight/dose, respectively. GV129606 was as effective as meropenem against septicemia in mice caused by ceftazidime-resistant Pseudomonas aeruginosa, exhibiting an ED50 of 0.33 mg/kg/dose.

scholarly journals In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

1989 ◽  
Vol 33 (8) ◽  
pp. 1167-1173 ◽  
Author(s):  
S Nakamura ◽  
A Minami ◽  
K Nakata ◽  
N Kurobe ◽  
K Kouno ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities

scholarly journals Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.

1991 ◽  
Vol 35 (1) ◽  
pp. 14-19 ◽  
Author(s):  
M Limbert ◽  
D Isert ◽  
N Klesel ◽  
A Markus ◽  
K Seeger ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Antibacterial Activities
Sign in / Sign up

Export Citation Format

Share Document